Frontiers in oncology · 2026
Primary healthcare-friendly prostate cancer prediction model using routine clinical parameters: a multicenter study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Ming, Li Tingting, Yang ShuPing, Zhou You, Lin Hanzong, Lan Jinxin, Zhang Xiaoqian, Yang Xiao, Zhou Jiguang, Lyu Guorong
Аннотация
OBJECTIVE: This study aimed to develop and validate a nomogram model integrating routinely available parameters, making it applicable to primary healthcare settings for optimizing prostate cancer (PCa) risk stratification in patients with elevated prostate-specific antigen (PSA) levels, aiming to reduce unnecessary biopsies.
METHODS: This study included a retrospective cohort of 2, 844 patients who underwent prostate biopsy (885 malignant and 1, 959 benign cases), who were randomly allocated to a training set and an internal validation set in a 7:3 ratio. Independent predictive factors were selected through univariate analyses and multivariate logistic regression analyses, and a nomogram was constructed. The model's performance was evaluated using Receiver Operating Characteristic (ROC) curve analysis, precision-recall (PR) curves, calibration curve, and decision curve analysis (DCA). Further validation was conducted using an external independent dataset (n = 281; 93 malignant and 188 benign cases) to assess the model's generalizability.
RESULTS: The nomogram model incorporated prostate volume, total PSA (tPSA), free-to-total PSA ratio (f/t PSA), and age, demonstrating discriminative performance with AUC values of 0.816 (95% CI: 0.796-0.836; training set), 0.833 (95% CI: 0.802-0.862; internal validation set), and 0.776 (95% CI: 0.720-0.832; external validation set). Its clinically acceptable performance outperformed that of individual parameters in the training set (all p-values <0.001 by Delong's test). The ROC curve and PR curve both demonstrated the robust predictive performance of the prediction model across all three study cohorts. The calibration curve showed strong agreement between the predicted probability and actual risk. DCA confirmed clinical net benefit across a wide range of risk thresholds.
CONCLUSION: This nomogram provides a non-invasive, cost-effective, individualized PCa risk assessment tool for Chinese patients with elevated PSA levels. Its generalizability was confirmed through external validation, demonstrating effectiveness in optimizing biopsy decisions and suitability for primary healthcare settings, thereby reducing healthcare burden.
METHODS: This study included a retrospective cohort of 2, 844 patients who underwent prostate biopsy (885 malignant and 1, 959 benign cases), who were randomly allocated to a training set and an internal validation set in a 7:3 ratio. Independent predictive factors were selected through univariate analyses and multivariate logistic regression analyses, and a nomogram was constructed. The model's performance was evaluated using Receiver Operating Characteristic (ROC) curve analysis, precision-recall (PR) curves, calibration curve, and decision curve analysis (DCA). Further validation was conducted using an external independent dataset (n = 281; 93 malignant and 188 benign cases) to assess the model's generalizability.
RESULTS: The nomogram model incorporated prostate volume, total PSA (tPSA), free-to-total PSA ratio (f/t PSA), and age, demonstrating discriminative performance with AUC values of 0.816 (95% CI: 0.796-0.836; training set), 0.833 (95% CI: 0.802-0.862; internal validation set), and 0.776 (95% CI: 0.720-0.832; external validation set). Its clinically acceptable performance outperformed that of individual parameters in the training set (all p-values <0.001 by Delong's test). The ROC curve and PR curve both demonstrated the robust predictive performance of the prediction model across all three study cohorts. The calibration curve showed strong agreement between the predicted probability and actual risk. DCA confirmed clinical net benefit across a wide range of risk thresholds.
CONCLUSION: This nomogram provides a non-invasive, cost-effective, individualized PCa risk assessment tool for Chinese patients with elevated PSA levels. Its generalizability was confirmed through external validation, demonstrating effectiveness in optimizing biopsy decisions and suitability for primary healthcare settings, thereby reducing healthcare burden.